Betta Pharmaceuticals Co Ltd (Betta Pharmaceuticals) discovers, develops, and supplies drugs for the treatment of cancer and diabetes. Its products include icotinib hydrochloride, an orally administered small-molecule, a reversible tyrosine kinase inhibitor for treating locally advanced or metastatic non-small cell lung cancer; and ensartinib hydrochloride capsules to treat ALK-mutated advanced non-small cell lung cancer. The company has also developed beantine, a macromolecular biological product for the treatment of recurrent non-small lung cancer. Betta Pharmaceuticals is developing its pipeline with small and macromolecule products for multiple cancer treatments. The company operates research and development centers in Hangzhou and Beijing, China and San Diego, the US. Betta Pharmaceuticals is headquartered in Hangzhou, Zhejiang, China.
Betta Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
Products |
---|
Pipeline: |
Icotinib |
Ensartinib |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In January, the company received approval from the State Food and Drug Administration for the clinical trial application of BPI-520105 tablets. |
2023 | Regulatory Approval | In February, the company received the notice of drug clinical trial approval issued by the State Drug Administration. |
2023 | Others | In January, the company's BPB-101 double antibody injection clinical trial application accepted by the State Drug Administration. |
Competitor Comparison
Key Parameters | Betta Pharmaceuticals Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Cachet Pharmaceutical Co Ltd | Walvax Biotechnology Co Ltd | Beijing SL Pharmaceutical Co Ltd |
---|---|---|---|---|---|
Headquarters | China | China | China | China | China |
City | Hangzhou | Shanghai | Beijing | Kunming | Beijing |
State/Province | Zhejiang | Shanghai | Beijing | Yunnan | Beijing |
No. of Employees | 1,961 | 40,370 | 2,294 | 2,388 | 757 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Ding Lieming | Chairman; Chief Executive Officer; General Manager | Executive Board | 2013 | 60 |
Tong Jia | Director; Chief Executive Officer | Executive Board | 2021 | 46 |
Fan Jianxun | Vice President; Director; Chief Financial Officer | Executive Board | 2021 | 52 |
Wan Jiang | Senior Vice President; Chief Operating Officer; Director | Executive Board | 2017 | 55 |
Jiabing Wang | Director; Senior Vice President | Executive Board | 2019 | 60 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer